| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 84 | 2025 | 1171 | 8.810 |
Why?
|
| Ependymoma | 40 | 2024 | 177 | 8.050 |
Why?
|
| Glioma | 32 | 2024 | 354 | 3.960 |
Why?
|
| Astrocytoma | 19 | 2023 | 122 | 3.630 |
Why?
|
| Rhabdoid Tumor | 17 | 2025 | 98 | 3.060 |
Why?
|
| Central Nervous System Neoplasms | 20 | 2025 | 149 | 3.000 |
Why?
|
| Brain Stem Neoplasms | 19 | 2024 | 89 | 2.700 |
Why?
|
| Glioblastoma | 18 | 2019 | 326 | 2.660 |
Why?
|
| Medulloblastoma | 24 | 2023 | 198 | 2.620 |
Why?
|
| Gene Expression Regulation, Neoplastic | 27 | 2025 | 1356 | 2.170 |
Why?
|
| Proto-Oncogene Proteins B-raf | 14 | 2023 | 212 | 2.040 |
Why?
|
| Gene Expression Profiling | 27 | 2024 | 1706 | 1.860 |
Why?
|
| Cerebellar Neoplasms | 15 | 2023 | 156 | 1.730 |
Why?
|
| Biomarkers, Tumor | 17 | 2019 | 1181 | 1.680 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2022 | 964 | 1.630 |
Why?
|
| Child | 127 | 2025 | 20883 | 1.490 |
Why?
|
| Teratoma | 9 | 2022 | 105 | 1.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2023 | 1565 | 1.340 |
Why?
|
| Infratentorial Neoplasms | 7 | 2024 | 60 | 1.330 |
Why?
|
| Craniopharyngioma | 9 | 2020 | 82 | 1.320 |
Why?
|
| Child, Preschool | 80 | 2025 | 10517 | 1.150 |
Why?
|
| Antineoplastic Agents | 19 | 2024 | 2061 | 1.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 20 | 2016 | 769 | 1.040 |
Why?
|
| Humans | 214 | 2025 | 129650 | 0.990 |
Why?
|
| Spinal Cord Neoplasms | 5 | 2014 | 40 | 0.990 |
Why?
|
| Cell Line, Tumor | 33 | 2025 | 3215 | 0.970 |
Why?
|
| Pons | 5 | 2015 | 30 | 0.950 |
Why?
|
| Immunophenotyping | 3 | 2017 | 311 | 0.930 |
Why?
|
| Adolescent | 80 | 2025 | 20393 | 0.910 |
Why?
|
| Mutation | 17 | 2024 | 3717 | 0.860 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2011 | 69 | 0.750 |
Why?
|
| Immunohistochemistry | 9 | 2017 | 1698 | 0.740 |
Why?
|
| Nuclear Proteins | 6 | 2017 | 663 | 0.730 |
Why?
|
| Radiation Injuries | 4 | 2019 | 135 | 0.730 |
Why?
|
| Infant | 49 | 2025 | 9024 | 0.730 |
Why?
|
| Hematology | 1 | 2021 | 14 | 0.730 |
Why?
|
| Drug Screening Assays, Antitumor | 5 | 2021 | 195 | 0.730 |
Why?
|
| Pituitary Neoplasms | 6 | 2020 | 184 | 0.720 |
Why?
|
| Neurofibromatosis 1 | 5 | 2024 | 47 | 0.720 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2017 | 317 | 0.710 |
Why?
|
| Prognosis | 29 | 2023 | 3794 | 0.690 |
Why?
|
| Ganglioglioma | 6 | 2017 | 31 | 0.680 |
Why?
|
| Cell Cycle Proteins | 8 | 2022 | 586 | 0.640 |
Why?
|
| Pyrimidinones | 5 | 2025 | 103 | 0.630 |
Why?
|
| Cell Proliferation | 22 | 2022 | 2391 | 0.630 |
Why?
|
| Male | 95 | 2025 | 63681 | 0.620 |
Why?
|
| Female | 93 | 2025 | 68776 | 0.610 |
Why?
|
| Transcriptome | 8 | 2023 | 887 | 0.590 |
Why?
|
| Radiation Tolerance | 6 | 2022 | 100 | 0.570 |
Why?
|
| SOXE Transcription Factors | 2 | 2016 | 18 | 0.570 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2017 | 759 | 0.570 |
Why?
|
| DNA Mutational Analysis | 3 | 2015 | 387 | 0.560 |
Why?
|
| Neoplasm Proteins | 3 | 2012 | 424 | 0.560 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2014 | 958 | 0.560 |
Why?
|
| Epigenesis, Genetic | 6 | 2021 | 613 | 0.550 |
Why?
|
| NF-kappa B | 2 | 2020 | 653 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2024 | 3408 | 0.540 |
Why?
|
| Brain | 11 | 2020 | 2679 | 0.540 |
Why?
|
| SMARCB1 Protein | 3 | 2025 | 29 | 0.520 |
Why?
|
| Craniotomy | 3 | 2009 | 69 | 0.510 |
Why?
|
| Cisplatin | 3 | 2016 | 300 | 0.510 |
Why?
|
| Myeloid Cells | 2 | 2015 | 143 | 0.500 |
Why?
|
| Neurofibroma, Plexiform | 3 | 2024 | 9 | 0.500 |
Why?
|
| Supratentorial Neoplasms | 3 | 2019 | 19 | 0.490 |
Why?
|
| Apoptosis | 18 | 2024 | 2503 | 0.490 |
Why?
|
| Indoles | 6 | 2017 | 387 | 0.490 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2012 | 11 | 0.480 |
Why?
|
| Epithelioid Cells | 1 | 2015 | 8 | 0.480 |
Why?
|
| Pilomatrixoma | 1 | 2015 | 3 | 0.480 |
Why?
|
| Survivors | 3 | 2023 | 464 | 0.470 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2020 | 71 | 0.470 |
Why?
|
| Gene Expression | 4 | 2015 | 1472 | 0.460 |
Why?
|
| Sulfonamides | 6 | 2017 | 496 | 0.460 |
Why?
|
| Radiation | 2 | 2021 | 24 | 0.460 |
Why?
|
| Meningeal Neoplasms | 2 | 2011 | 93 | 0.460 |
Why?
|
| Histones | 6 | 2021 | 588 | 0.460 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2020 | 432 | 0.450 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2019 | 328 | 0.450 |
Why?
|
| Chemoradiotherapy | 6 | 2019 | 210 | 0.440 |
Why?
|
| DNA Methylation | 8 | 2021 | 607 | 0.440 |
Why?
|
| Cancer Vaccines | 2 | 2010 | 164 | 0.440 |
Why?
|
| Phenotype | 8 | 2024 | 3076 | 0.440 |
Why?
|
| Autophagy | 4 | 2019 | 268 | 0.430 |
Why?
|
| RNA, Messenger | 11 | 2017 | 2708 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2025 | 891 | 0.430 |
Why?
|
| Quinazolines | 5 | 2022 | 244 | 0.430 |
Why?
|
| Germinoma | 2 | 2022 | 13 | 0.420 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 195 | 0.420 |
Why?
|
| Pediatric Nursing | 2 | 2013 | 39 | 0.420 |
Why?
|
| Neoplasms, Radiation-Induced | 8 | 2014 | 71 | 0.410 |
Why?
|
| Adult | 44 | 2025 | 35576 | 0.400 |
Why?
|
| Combined Modality Therapy | 13 | 2019 | 1206 | 0.400 |
Why?
|
| Acetylcysteine | 1 | 2013 | 146 | 0.400 |
Why?
|
| Survival Rate | 14 | 2020 | 1877 | 0.400 |
Why?
|
| Medical Oncology | 3 | 2025 | 272 | 0.400 |
Why?
|
| Pyridones | 2 | 2025 | 159 | 0.390 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2019 | 131 | 0.390 |
Why?
|
| Aging | 3 | 2020 | 1776 | 0.390 |
Why?
|
| Fatal Outcome | 7 | 2021 | 300 | 0.390 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2016 | 40 | 0.380 |
Why?
|
| Microarray Analysis | 7 | 2017 | 122 | 0.380 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2007 | 69 | 0.380 |
Why?
|
| Receptor, ErbB-3 | 2 | 2015 | 45 | 0.380 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2022 | 638 | 0.370 |
Why?
|
| Brain Stem | 4 | 2023 | 98 | 0.370 |
Why?
|
| Tumor Cells, Cultured | 14 | 2019 | 940 | 0.370 |
Why?
|
| Chromosome Aberrations | 3 | 2023 | 150 | 0.370 |
Why?
|
| Retrospective Studies | 32 | 2025 | 14518 | 0.360 |
Why?
|
| Interleukin-6 | 1 | 2015 | 720 | 0.360 |
Why?
|
| Pyrimidines | 8 | 2019 | 459 | 0.360 |
Why?
|
| Acetaminophen | 1 | 2013 | 246 | 0.350 |
Why?
|
| Salvage Therapy | 3 | 2015 | 134 | 0.350 |
Why?
|
| Dance Therapy | 1 | 2010 | 3 | 0.340 |
Why?
|
| Young Adult | 22 | 2025 | 12426 | 0.340 |
Why?
|
| Pyrazoles | 6 | 2022 | 405 | 0.340 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2015 | 315 | 0.340 |
Why?
|
| MicroRNAs | 3 | 2012 | 678 | 0.340 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 4897 | 0.340 |
Why?
|
| Choroid Plexus Neoplasms | 3 | 2009 | 9 | 0.330 |
Why?
|
| Molecular Targeted Therapy | 4 | 2018 | 390 | 0.330 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2005 | 278 | 0.330 |
Why?
|
| Music Therapy | 1 | 2010 | 22 | 0.330 |
Why?
|
| Art Therapy | 1 | 2010 | 17 | 0.330 |
Why?
|
| Memory Disorders | 1 | 2011 | 168 | 0.330 |
Why?
|
| Transcription Factors | 6 | 2023 | 1651 | 0.330 |
Why?
|
| Cohort Studies | 12 | 2021 | 5420 | 0.330 |
Why?
|
| Blotting, Western | 10 | 2019 | 1205 | 0.330 |
Why?
|
| Cranial Irradiation | 4 | 2023 | 68 | 0.320 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 94 | 0.320 |
Why?
|
| Electrolytes | 1 | 2009 | 60 | 0.320 |
Why?
|
| Benzamides | 4 | 2024 | 207 | 0.310 |
Why?
|
| Cell Cycle | 11 | 2017 | 592 | 0.310 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 350 | 0.300 |
Why?
|
| Sodium | 1 | 2009 | 206 | 0.300 |
Why?
|
| Fluid Therapy | 1 | 2009 | 134 | 0.300 |
Why?
|
| Outpatients | 2 | 2019 | 370 | 0.300 |
Why?
|
| Vinblastine | 4 | 2020 | 69 | 0.300 |
Why?
|
| Brain Diseases | 2 | 2019 | 137 | 0.300 |
Why?
|
| Treatment Outcome | 20 | 2024 | 10230 | 0.290 |
Why?
|
| Dacarbazine | 2 | 2007 | 94 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2018 | 857 | 0.280 |
Why?
|
| Mesenchymoma | 1 | 2007 | 7 | 0.280 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 15 | 0.280 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2007 | 10 | 0.280 |
Why?
|
| DNA Repair Enzymes | 1 | 2007 | 21 | 0.270 |
Why?
|
| Radiotherapy | 4 | 2019 | 188 | 0.270 |
Why?
|
| Neuroblastoma | 6 | 1996 | 154 | 0.270 |
Why?
|
| Form Perception | 2 | 2005 | 11 | 0.270 |
Why?
|
| Chloroquine | 3 | 2017 | 52 | 0.270 |
Why?
|
| Neoplasms | 6 | 2024 | 2470 | 0.270 |
Why?
|
| DNA-Binding Proteins | 4 | 2024 | 1443 | 0.270 |
Why?
|
| Quality of Life | 4 | 2024 | 2704 | 0.260 |
Why?
|
| Bevacizumab | 3 | 2019 | 129 | 0.260 |
Why?
|
| High Mobility Group Proteins | 1 | 2006 | 42 | 0.260 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 1928 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2017 | 2012 | 0.260 |
Why?
|
| Infant, Newborn | 14 | 2020 | 5762 | 0.260 |
Why?
|
| Vascular Diseases | 1 | 2009 | 241 | 0.250 |
Why?
|
| Epigenomics | 4 | 2021 | 110 | 0.250 |
Why?
|
| B7-H1 Antigen | 2 | 2018 | 196 | 0.250 |
Why?
|
| Neutrophils | 1 | 2011 | 1205 | 0.250 |
Why?
|
| Cell Survival | 10 | 2020 | 1086 | 0.250 |
Why?
|
| Genetic Markers | 4 | 2006 | 338 | 0.250 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2014 | 331 | 0.250 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 570 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2019 | 132 | 0.240 |
Why?
|
| Tamoxifen | 3 | 2004 | 200 | 0.240 |
Why?
|
| Sirtuin 2 | 1 | 2025 | 24 | 0.240 |
Why?
|
| Sensory Thresholds | 1 | 2005 | 32 | 0.230 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 159 | 0.230 |
Why?
|
| Visual Fields | 1 | 2005 | 87 | 0.230 |
Why?
|
| ErbB Receptors | 3 | 2015 | 607 | 0.230 |
Why?
|
| Chordoma | 1 | 2024 | 16 | 0.230 |
Why?
|
| Signal Transduction | 5 | 2017 | 4925 | 0.230 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.220 |
Why?
|
| Retinal Diseases | 1 | 2025 | 88 | 0.220 |
Why?
|
| Pattern Recognition, Visual | 1 | 2005 | 98 | 0.220 |
Why?
|
| Bleomycin | 2 | 2009 | 244 | 0.220 |
Why?
|
| Cytokines | 3 | 2017 | 2017 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 1367 | 0.210 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 66 | 0.210 |
Why?
|
| Sarcoma, Ewing | 2 | 2017 | 89 | 0.200 |
Why?
|
| Genes, myc | 2 | 2020 | 50 | 0.200 |
Why?
|
| Cellular Senescence | 3 | 2019 | 181 | 0.200 |
Why?
|
| Pineal Gland | 1 | 2022 | 17 | 0.200 |
Why?
|
| Pinealoma | 1 | 2022 | 11 | 0.200 |
Why?
|
| Chromatin | 4 | 2020 | 479 | 0.200 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 634 | 0.190 |
Why?
|
| RNA, Small Interfering | 4 | 2012 | 587 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 744 | 0.190 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 162 | 0.190 |
Why?
|
| Polycomb Repressive Complex 1 | 2 | 2020 | 48 | 0.190 |
Why?
|
| Asparaginase | 2 | 1992 | 29 | 0.190 |
Why?
|
| Mice | 14 | 2025 | 16937 | 0.190 |
Why?
|
| Vaccination | 2 | 2010 | 1348 | 0.190 |
Why?
|
| Necrosis | 4 | 2019 | 232 | 0.190 |
Why?
|
| Meningioma | 2 | 2009 | 82 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 64 | 0.190 |
Why?
|
| Neoplasm Staging | 6 | 2017 | 1295 | 0.180 |
Why?
|
| Cysts | 2 | 1999 | 109 | 0.180 |
Why?
|
| Receptor, trkC | 1 | 2021 | 10 | 0.180 |
Why?
|
| Italy | 1 | 2021 | 100 | 0.180 |
Why?
|
| Hydrocephalus | 1 | 2022 | 107 | 0.180 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2021 | 65 | 0.180 |
Why?
|
| Karyotyping | 4 | 2010 | 107 | 0.180 |
Why?
|
| Receptor, trkB | 1 | 2021 | 30 | 0.180 |
Why?
|
| Cerebellum | 4 | 2023 | 219 | 0.180 |
Why?
|
| Transcription Factor RelA | 2 | 2019 | 81 | 0.180 |
Why?
|
| Vincristine | 3 | 2016 | 109 | 0.180 |
Why?
|
| Pituitary Diseases | 1 | 2020 | 21 | 0.180 |
Why?
|
| Middle Aged | 14 | 2024 | 31154 | 0.180 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 1004 | 0.170 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 388 | 0.170 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 60 | 0.170 |
Why?
|
| Frontal Lobe | 1 | 2001 | 154 | 0.170 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2020 | 37 | 0.170 |
Why?
|
| Animals | 19 | 2025 | 35361 | 0.170 |
Why?
|
| Cluster Analysis | 2 | 2013 | 482 | 0.170 |
Why?
|
| Flow Cytometry | 5 | 2019 | 1156 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2535 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 2 | 2006 | 106 | 0.170 |
Why?
|
| Pituitary Gland | 1 | 2020 | 148 | 0.170 |
Why?
|
| Anilides | 2 | 2010 | 73 | 0.170 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2020 | 36 | 0.170 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 71 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 87 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2005 | 573 | 0.160 |
Why?
|
| Gene Ontology | 2 | 2021 | 51 | 0.160 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2019 | 17 | 0.160 |
Why?
|
| Carcinoma | 1 | 2001 | 217 | 0.160 |
Why?
|
| Drug Delivery Systems | 2 | 2015 | 336 | 0.160 |
Why?
|
| Aged | 9 | 2024 | 22103 | 0.160 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 1434 | 0.160 |
Why?
|
| Transplantation, Autologous | 3 | 2019 | 211 | 0.160 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2019 | 12 | 0.160 |
Why?
|
| Optic Chiasm | 1 | 2019 | 19 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 380 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1999 | 123 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 211 | 0.160 |
Why?
|
| Age Factors | 4 | 2017 | 3144 | 0.150 |
Why?
|
| Deoxycytidine | 1 | 2020 | 165 | 0.150 |
Why?
|
| Pteridines | 2 | 2016 | 22 | 0.150 |
Why?
|
| Radiosurgery | 2 | 2014 | 321 | 0.150 |
Why?
|
| Protein Kinase C | 1 | 2000 | 259 | 0.150 |
Why?
|
| Disease Progression | 5 | 2023 | 2635 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 474 | 0.150 |
Why?
|
| Neoplasm Grading | 4 | 2021 | 285 | 0.150 |
Why?
|
| Carboplatin | 4 | 2020 | 140 | 0.150 |
Why?
|
| Spinal Neoplasms | 2 | 2017 | 29 | 0.150 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 648 | 0.150 |
Why?
|
| Stromal Cells | 1 | 2018 | 107 | 0.150 |
Why?
|
| Skull Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
|
| Adenoviridae | 1 | 1998 | 192 | 0.140 |
Why?
|
| Gingival Neoplasms | 1 | 1997 | 10 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 511 | 0.140 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 277 | 0.140 |
Why?
|
| Risk Factors | 6 | 2020 | 9765 | 0.140 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 25 | 0.140 |
Why?
|
| Drug Approval | 1 | 2018 | 88 | 0.140 |
Why?
|
| Computer Simulation | 2 | 2021 | 943 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 201 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 220 | 0.140 |
Why?
|
| Cyst Fluid | 1 | 2017 | 26 | 0.140 |
Why?
|
| Everolimus | 1 | 2017 | 88 | 0.140 |
Why?
|
| Consensus | 3 | 2025 | 616 | 0.140 |
Why?
|
| Urine | 1 | 2017 | 60 | 0.140 |
Why?
|
| Genes, p16 | 1 | 2017 | 19 | 0.140 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1997 | 4 | 0.140 |
Why?
|
| E2F Transcription Factors | 1 | 2017 | 59 | 0.140 |
Why?
|
| Survival Analysis | 6 | 2023 | 1274 | 0.140 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2010 | 99 | 0.140 |
Why?
|
| Morpholines | 1 | 2017 | 122 | 0.140 |
Why?
|
| Re-Irradiation | 1 | 2016 | 8 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2024 | 814 | 0.130 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2016 | 29 | 0.130 |
Why?
|
| Phosphorylation | 3 | 2017 | 1713 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 1998 | 292 | 0.130 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2016 | 31 | 0.130 |
Why?
|
| Neuroimaging | 1 | 2019 | 279 | 0.130 |
Why?
|
| Bilirubin | 1 | 2016 | 96 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 232 | 0.130 |
Why?
|
| Electric Stimulation Therapy | 1 | 2017 | 77 | 0.130 |
Why?
|
| Mutation, Missense | 2 | 2016 | 317 | 0.130 |
Why?
|
| Repressor Proteins | 3 | 2023 | 406 | 0.130 |
Why?
|
| Etoposide | 3 | 2007 | 148 | 0.130 |
Why?
|
| Societies, Medical | 2 | 2025 | 751 | 0.130 |
Why?
|
| Circle of Willis | 1 | 1995 | 7 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 206 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 326 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2012 | 40 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 7086 | 0.120 |
Why?
|
| DNA Repair | 2 | 2024 | 207 | 0.120 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 366 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 171 | 0.120 |
Why?
|
| EGF Family of Proteins | 1 | 2015 | 17 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 431 | 0.120 |
Why?
|
| Cannabinoids | 1 | 2017 | 153 | 0.120 |
Why?
|
| Receptor, EphA2 | 1 | 2015 | 20 | 0.120 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 22 | 0.120 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 132 | 0.120 |
Why?
|
| Radiation, Ionizing | 2 | 2012 | 76 | 0.120 |
Why?
|
| Visual Perception | 1 | 1997 | 163 | 0.120 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2012 | 63 | 0.120 |
Why?
|
| Time Factors | 4 | 2015 | 6556 | 0.120 |
Why?
|
| Genome, Human | 2 | 2014 | 393 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 295 | 0.120 |
Why?
|
| Palliative Care | 2 | 2013 | 725 | 0.120 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2015 | 87 | 0.120 |
Why?
|
| Genetic Variation | 1 | 2019 | 937 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2015 | 96 | 0.110 |
Why?
|
| Spatial Learning | 1 | 2014 | 3 | 0.110 |
Why?
|
| Reversal Learning | 1 | 2014 | 10 | 0.110 |
Why?
|
| Activin Receptors, Type I | 1 | 2014 | 7 | 0.110 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 524 | 0.110 |
Why?
|
| Cerebrovascular Disorders | 1 | 1995 | 90 | 0.110 |
Why?
|
| Leukapheresis | 2 | 2006 | 21 | 0.110 |
Why?
|
| Cell Differentiation | 5 | 2025 | 1902 | 0.110 |
Why?
|
| Microscopy, Electron | 2 | 2007 | 426 | 0.110 |
Why?
|
| Psychomotor Performance | 1 | 1997 | 313 | 0.110 |
Why?
|
| Thyroxine | 1 | 2014 | 62 | 0.110 |
Why?
|
| Enzyme Inhibitors | 5 | 2020 | 827 | 0.110 |
Why?
|
| Data Collection | 2 | 2014 | 650 | 0.110 |
Why?
|
| Health Status | 1 | 1999 | 755 | 0.110 |
Why?
|
| Professional Practice | 1 | 2014 | 63 | 0.110 |
Why?
|
| Hypothyroidism | 1 | 2014 | 70 | 0.110 |
Why?
|
| Deoxyribose | 1 | 2013 | 6 | 0.110 |
Why?
|
| Genes, p53 | 2 | 2005 | 70 | 0.110 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1993 | 12 | 0.110 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2013 | 18 | 0.110 |
Why?
|
| Microdissection | 1 | 2013 | 15 | 0.110 |
Why?
|
| Chromosomes | 2 | 2024 | 101 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2018 | 263 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 68 | 0.110 |
Why?
|
| Receptors, IgG | 1 | 2013 | 74 | 0.110 |
Why?
|
| Dexamethasone | 2 | 2019 | 346 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 1207 | 0.100 |
Why?
|
| Registries | 2 | 2018 | 1896 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2013 | 105 | 0.100 |
Why?
|
| Germ-Line Mutation | 2 | 2005 | 140 | 0.100 |
Why?
|
| RNA, Neoplasm | 2 | 2009 | 88 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 2282 | 0.100 |
Why?
|
| Neurology | 1 | 2014 | 103 | 0.100 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 38 | 0.100 |
Why?
|
| Infant, Premature | 1 | 1997 | 541 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 224 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 52 | 0.100 |
Why?
|
| Receptors, Opioid | 1 | 2012 | 24 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4063 | 0.100 |
Why?
|
| Biopsy | 3 | 2011 | 1097 | 0.100 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1992 | 6 | 0.100 |
Why?
|
| Monocytes | 1 | 2015 | 551 | 0.100 |
Why?
|
| Incidence | 4 | 2011 | 2644 | 0.100 |
Why?
|
| Organotechnetium Compounds | 1 | 1992 | 10 | 0.100 |
Why?
|
| DNA Damage | 2 | 2016 | 384 | 0.100 |
Why?
|
| Child Development | 1 | 1997 | 457 | 0.100 |
Why?
|
| Memory | 1 | 2014 | 255 | 0.100 |
Why?
|
| Oximes | 1 | 1992 | 22 | 0.100 |
Why?
|
| Central Nervous System | 1 | 2014 | 257 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 505 | 0.100 |
Why?
|
| England | 4 | 1996 | 72 | 0.100 |
Why?
|
| Cerebral Infarction | 1 | 1992 | 42 | 0.090 |
Why?
|
| Cell Movement | 2 | 2013 | 945 | 0.090 |
Why?
|
| Glutathione | 1 | 2013 | 348 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1992 | 77 | 0.090 |
Why?
|
| Radon | 3 | 1996 | 17 | 0.090 |
Why?
|
| Protein Precursors | 1 | 2012 | 127 | 0.090 |
Why?
|
| SEER Program | 1 | 2012 | 206 | 0.090 |
Why?
|
| Autopsy | 1 | 2011 | 94 | 0.090 |
Why?
|
| Aptitude Tests | 1 | 2011 | 4 | 0.090 |
Why?
|
| Spinal Cord | 1 | 2014 | 356 | 0.090 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 170 | 0.090 |
Why?
|
| Patient Selection | 1 | 2015 | 663 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1952 | 0.090 |
Why?
|
| Transfusion Reaction | 1 | 1991 | 43 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2015 | 387 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 1269 | 0.090 |
Why?
|
| Amnesia | 1 | 2011 | 43 | 0.090 |
Why?
|
| Cyclophosphamide | 2 | 2005 | 232 | 0.090 |
Why?
|
| Neurosurgery | 1 | 2011 | 37 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 1 | 1992 | 107 | 0.090 |
Why?
|
| Glucocorticoids | 2 | 2019 | 575 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 169 | 0.090 |
Why?
|
| Program Development | 1 | 2013 | 357 | 0.090 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 1015 | 0.090 |
Why?
|
| Azepines | 3 | 2019 | 89 | 0.090 |
Why?
|
| Reoperation | 3 | 1999 | 545 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2017 | 371 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2019 | 1587 | 0.090 |
Why?
|
| Graft vs Host Disease | 2 | 2010 | 241 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 1201 | 0.090 |
Why?
|
| Creativity | 1 | 2010 | 10 | 0.090 |
Why?
|
| Nursing Methodology Research | 1 | 2010 | 46 | 0.080 |
Why?
|
| Psychology, Child | 1 | 2010 | 36 | 0.080 |
Why?
|
| Intracellular Space | 1 | 2010 | 69 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2011 | 209 | 0.080 |
Why?
|
| Papilloma | 1 | 2009 | 48 | 0.080 |
Why?
|
| Surgeons | 1 | 2014 | 261 | 0.080 |
Why?
|
| Medical Futility | 1 | 2010 | 24 | 0.080 |
Why?
|
| Sample Size | 1 | 2010 | 116 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 1993 | 427 | 0.080 |
Why?
|
| United Kingdom | 3 | 1996 | 257 | 0.080 |
Why?
|
| Hospice Care | 1 | 2013 | 200 | 0.080 |
Why?
|
| Antidiuretic Agents | 1 | 2009 | 7 | 0.080 |
Why?
|
| Nausea | 1 | 2010 | 110 | 0.080 |
Why?
|
| Home Care Services | 1 | 2013 | 246 | 0.080 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2009 | 11 | 0.080 |
Why?
|
| Hypernatremia | 1 | 2009 | 9 | 0.080 |
Why?
|
| Reaction Time | 2 | 2005 | 410 | 0.080 |
Why?
|
| Terminal Care | 1 | 2013 | 237 | 0.080 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 42 | 0.080 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 19 | 0.080 |
Why?
|
| Erythrocyte Transfusion | 1 | 1991 | 181 | 0.080 |
Why?
|
| Astrocytes | 1 | 2011 | 201 | 0.080 |
Why?
|
| Hemangioma | 1 | 2009 | 44 | 0.080 |
Why?
|
| Epilepsy | 1 | 2013 | 329 | 0.080 |
Why?
|
| Hyponatremia | 1 | 2009 | 40 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2016 | 187 | 0.080 |
Why?
|
| Shock, Septic | 1 | 1991 | 209 | 0.080 |
Why?
|
| Single-Blind Method | 1 | 2009 | 271 | 0.080 |
Why?
|
| Leukemia, Lymphoid | 1 | 1988 | 27 | 0.070 |
Why?
|
| Brain Abscess | 1 | 1988 | 10 | 0.070 |
Why?
|
| Cranial Fossa, Posterior | 2 | 1998 | 17 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2001 | 210 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 231 | 0.070 |
Why?
|
| Candidiasis | 1 | 1988 | 56 | 0.070 |
Why?
|
| Glucose | 1 | 2013 | 1003 | 0.070 |
Why?
|
| Ki-67 Antigen | 2 | 2017 | 109 | 0.070 |
Why?
|
| Herpesvirus 3, Human | 1 | 2011 | 331 | 0.070 |
Why?
|
| Anemia, Sickle Cell | 1 | 1991 | 254 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2001 | 381 | 0.070 |
Why?
|
| Focus Groups | 1 | 2010 | 453 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 213 | 0.070 |
Why?
|
| Herpes Zoster | 1 | 2011 | 317 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 596 | 0.070 |
Why?
|
| Disease Management | 2 | 2025 | 589 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2019 | 868 | 0.070 |
Why?
|
| Anxiety | 2 | 2014 | 966 | 0.070 |
Why?
|
| Paresis | 1 | 2007 | 30 | 0.070 |
Why?
|
| Aurora Kinases | 3 | 2012 | 29 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 530 | 0.070 |
Why?
|
| Thymidine | 1 | 2006 | 59 | 0.070 |
Why?
|
| Air Pollutants, Radioactive | 2 | 1996 | 3 | 0.070 |
Why?
|
| Aurora Kinase A | 3 | 2012 | 55 | 0.070 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2006 | 9 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2010 | 431 | 0.070 |
Why?
|
| Antigens, CD34 | 1 | 2006 | 88 | 0.070 |
Why?
|
| Multigene Family | 1 | 2007 | 199 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2024 | 592 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2007 | 190 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2012 | 132 | 0.060 |
Why?
|
| Diet | 1 | 1993 | 1213 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2073 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2007 | 135 | 0.060 |
Why?
|
| Genetic Linkage | 1 | 2006 | 299 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 1838 | 0.060 |
Why?
|
| Piperazines | 2 | 2022 | 342 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 1998 | 312 | 0.060 |
Why?
|
| Cell Division | 3 | 2010 | 797 | 0.060 |
Why?
|
| Neural Crest | 1 | 2006 | 114 | 0.060 |
Why?
|
| Catheterization, Peripheral | 2 | 2001 | 104 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 166 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 1998 | 436 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 335 | 0.060 |
Why?
|
| Colorado | 3 | 2022 | 4421 | 0.060 |
Why?
|
| Triazoles | 2 | 2019 | 152 | 0.060 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 313 | 0.060 |
Why?
|
| Retroviridae | 3 | 1994 | 99 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2011 | 226 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2019 | 683 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2012 | 340 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2005 | 89 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 759 | 0.060 |
Why?
|
| Radiography | 3 | 2014 | 798 | 0.060 |
Why?
|
| Fluorescein Angiography | 1 | 2025 | 143 | 0.060 |
Why?
|
| Tertiary Care Centers | 1 | 2025 | 151 | 0.060 |
Why?
|
| Pain | 1 | 2010 | 789 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 14 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2024 | 1418 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2001 | 381 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2012 | 7133 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2005 | 242 | 0.050 |
Why?
|
| Intelligence Tests | 1 | 2023 | 58 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 2119 | 0.050 |
Why?
|
| RNA, Small Nuclear | 1 | 2023 | 35 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 1098 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2010 | 636 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2023 | 31 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2025 | 187 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 485 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 487 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2024 | 199 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2010 | 1235 | 0.050 |
Why?
|
| Laminectomy | 2 | 2001 | 29 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2023 | 35 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 191 | 0.050 |
Why?
|
| Vitamins | 2 | 1994 | 174 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 158 | 0.050 |
Why?
|
| Caspases | 1 | 2004 | 245 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2005 | 391 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2016 | 840 | 0.050 |
Why?
|
| Visual Acuity | 1 | 2025 | 322 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2012 | 41 | 0.050 |
Why?
|
| Cytidine Deaminase | 1 | 2023 | 57 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1119 | 0.050 |
Why?
|
| Tryptophan | 1 | 2024 | 179 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 168 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 883 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2003 | 129 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 779 | 0.050 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.050 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2001 | 13 | 0.050 |
Why?
|
| Spheroids, Cellular | 2 | 2012 | 77 | 0.050 |
Why?
|
| Transfection | 3 | 1994 | 911 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2001 | 41 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 231 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 882 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2001 | 17 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2001 | 24 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 14 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 622 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2001 | 104 | 0.050 |
Why?
|
| Mesentery | 1 | 2001 | 47 | 0.050 |
Why?
|
| Histone Deacetylases | 1 | 2023 | 212 | 0.050 |
Why?
|
| Remission Induction | 2 | 2012 | 272 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 202 | 0.050 |
Why?
|
| Leukemia | 2 | 2010 | 230 | 0.040 |
Why?
|
| Neural Stem Cells | 2 | 2012 | 143 | 0.040 |
Why?
|
| RNA Polymerase II | 1 | 2024 | 317 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 52 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 2 | 1992 | 274 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2001 | 87 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 188 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 178 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 115 | 0.040 |
Why?
|
| Cell Fusion | 1 | 2020 | 51 | 0.040 |
Why?
|
| Instillation, Drug | 1 | 1999 | 10 | 0.040 |
Why?
|
| Catheterization | 1 | 2001 | 175 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 1999 | 34 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2020 | 68 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1999 | 72 | 0.040 |
Why?
|
| Low Back Pain | 1 | 2001 | 105 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 1038 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 41 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 351 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2019 | 97 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 70 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2019 | 53 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 61 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 1998 | 26 | 0.040 |
Why?
|
| Pyridines | 2 | 2012 | 478 | 0.040 |
Why?
|
| Antigens, CD | 2 | 1998 | 489 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 176 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2018 | 55 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2000 | 391 | 0.040 |
Why?
|
| Lysine | 1 | 2020 | 286 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 1085 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 588 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2009 | 2483 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 1999 | 167 | 0.040 |
Why?
|
| Atmospheric Pressure | 1 | 2017 | 23 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 3083 | 0.040 |
Why?
|
| Diencephalon | 1 | 2017 | 13 | 0.040 |
Why?
|
| Receptors, HIV | 1 | 2017 | 26 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2018 | 149 | 0.040 |
Why?
|
| Mucin-1 | 1 | 2017 | 20 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 141 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2017 | 38 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 33 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2018 | 376 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2017 | 82 | 0.030 |
Why?
|
| Immune System | 1 | 1998 | 175 | 0.030 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 56 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 697 | 0.030 |
Why?
|
| Perceptual Closure | 1 | 1997 | 1 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 119 | 0.030 |
Why?
|
| Perceptual Masking | 1 | 1997 | 13 | 0.030 |
Why?
|
| Volition | 1 | 1997 | 30 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2017 | 92 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2020 | 547 | 0.030 |
Why?
|
| Cetuximab | 1 | 2017 | 94 | 0.030 |
Why?
|
| Benzodiazepinones | 1 | 2016 | 17 | 0.030 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 109 | 0.030 |
Why?
|
| Dasatinib | 1 | 2016 | 54 | 0.030 |
Why?
|
| Genotype | 1 | 2001 | 1839 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 120 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 640 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 1998 | 355 | 0.030 |
Why?
|
| Urea | 1 | 2016 | 77 | 0.030 |
Why?
|
| Carcinogens, Environmental | 1 | 1996 | 7 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 310 | 0.030 |
Why?
|
| Hospital Bed Capacity | 1 | 1996 | 25 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1995 | 34 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1998 | 375 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 2 | 2012 | 90 | 0.030 |
Why?
|
| Thiophenes | 1 | 2016 | 118 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 282 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 599 | 0.030 |
Why?
|
| Amphiregulin | 1 | 2015 | 25 | 0.030 |
Why?
|
| Mitosis | 1 | 2016 | 180 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1304 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 345 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 582 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2015 | 24 | 0.030 |
Why?
|
| Gentamicins | 2 | 1992 | 54 | 0.030 |
Why?
|
| Demography | 1 | 1996 | 279 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 1995 | 109 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 608 | 0.030 |
Why?
|
| Hearing | 1 | 2016 | 135 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 143 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 315 | 0.030 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2014 | 38 | 0.030 |
Why?
|
| Personality Assessment | 1 | 2014 | 82 | 0.030 |
Why?
|
| Maze Learning | 1 | 2014 | 104 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1997 | 1288 | 0.030 |
Why?
|
| Urban Health | 1 | 1994 | 79 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1995 | 236 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 531 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 133 | 0.030 |
Why?
|
| Attention | 1 | 1997 | 438 | 0.030 |
Why?
|
| Environmental Exposure | 2 | 1996 | 462 | 0.030 |
Why?
|
| raf Kinases | 1 | 2013 | 11 | 0.030 |
Why?
|
| Cathepsin B | 1 | 2012 | 14 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 154 | 0.030 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 29 | 0.030 |
Why?
|
| Argonaute Proteins | 1 | 2012 | 28 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1622 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 137 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2015 | 332 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 330 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1994 | 516 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1993 | 220 | 0.020 |
Why?
|
| Exons | 1 | 2013 | 342 | 0.020 |
Why?
|
| Prenatal Care | 1 | 1994 | 276 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 399 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2012 | 45 | 0.020 |
Why?
|
| Catalysis | 1 | 2013 | 310 | 0.020 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1992 | 2 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 148 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 138 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 173 | 0.020 |
Why?
|
| Biomarkers | 1 | 2023 | 3973 | 0.020 |
Why?
|
| Pseudomonas fluorescens | 1 | 1991 | 3 | 0.020 |
Why?
|
| Hematoma | 1 | 1992 | 54 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 193 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 182 | 0.020 |
Why?
|
| Tubulin | 1 | 2012 | 137 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1993 | 265 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2012 | 173 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2011 | 115 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 400 | 0.020 |
Why?
|
| Acetylation | 1 | 2011 | 246 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 448 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 1991 | 122 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1992 | 271 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2010 | 21 | 0.020 |
Why?
|
| Adenosine | 1 | 2012 | 227 | 0.020 |
Why?
|
| Endotoxins | 1 | 1991 | 220 | 0.020 |
Why?
|
| Burkitt Lymphoma | 1 | 1991 | 56 | 0.020 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2010 | 44 | 0.020 |
Why?
|
| Base Sequence | 2 | 2010 | 2142 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 769 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 13 | 0.020 |
Why?
|
| Zebrafish | 1 | 2014 | 458 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 1642 | 0.020 |
Why?
|
| Superoxides | 1 | 2010 | 201 | 0.020 |
Why?
|
| Research | 1 | 2012 | 416 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2009 | 80 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 166 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 315 | 0.020 |
Why?
|
| Risk | 1 | 1992 | 854 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 35 | 0.020 |
Why?
|
| Claudins | 1 | 2009 | 25 | 0.020 |
Why?
|
| Genomics | 1 | 2014 | 716 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 252 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 171 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 875 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2012 | 743 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 451 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 850 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 545 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 1123 | 0.020 |
Why?
|
| Burns | 1 | 1992 | 286 | 0.020 |
Why?
|
| Amphotericin B | 1 | 1988 | 29 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 1127 | 0.020 |
Why?
|
| Recurrence | 2 | 2005 | 1007 | 0.020 |
Why?
|
| United States | 3 | 2014 | 13903 | 0.020 |
Why?
|
| Health Personnel | 1 | 2013 | 652 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1999 | 5406 | 0.020 |
Why?
|
| Leukemia, Myeloid | 2 | 1996 | 45 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2005 | 120 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1992 | 592 | 0.020 |
Why?
|
| Depression | 1 | 2014 | 1307 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3381 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2005 | 401 | 0.010 |
Why?
|
| Pedigree | 1 | 2005 | 487 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 786 | 0.010 |
Why?
|
| Kanamycin Kinase | 2 | 1994 | 4 | 0.010 |
Why?
|
| Acute Disease | 2 | 1996 | 980 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2004 | 245 | 0.010 |
Why?
|
| Body Weight | 1 | 2006 | 940 | 0.010 |
Why?
|
| Stem Cells | 1 | 2006 | 577 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 811 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1502 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2058 | 0.010 |
Why?
|
| Pregnancy | 1 | 1993 | 6402 | 0.010 |
Why?
|
| Equipment Design | 1 | 2001 | 514 | 0.010 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1994 | 42 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1996 | 153 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1994 | 84 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1994 | 270 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1994 | 267 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 1992 | 24 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 643 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 1992 | 128 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1992 | 166 | 0.010 |
Why?
|
| Probability | 1 | 1992 | 306 | 0.010 |
Why?
|
| Professional-Patient Relations | 1 | 1992 | 140 | 0.010 |
Why?
|
| Cytarabine | 1 | 1991 | 57 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1991 | 109 | 0.010 |
Why?
|
| Employment | 1 | 1992 | 167 | 0.010 |
Why?
|
| Methotrexate | 1 | 1991 | 249 | 0.010 |
Why?
|
| Social Support | 1 | 1992 | 588 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 2832 | 0.000 |
Why?
|
| DNA | 1 | 1992 | 1400 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1992 | 4083 | 0.000 |
Why?
|
| Iodine Compounds | 1 | 1951 | 3 | 0.000 |
Why?
|
| Hyperthyroidism | 1 | 1951 | 28 | 0.000 |
Why?
|
| Iodine | 1 | 1951 | 24 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1951 | 143 | 0.000 |
Why?
|